Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayChemo-Free Maintenance Combo Promising in Pancreatic Cancer

This paring of PARP inhibitor and immune checkpoint inhibitor may be a viable non-cytotoxic maintenance therapy option for patients with platinum-sensitive pancreatic ductal adenocarcinoma. At a median follow-up of 23.0 months, combining the PARP inhibitor niraparib with the anti CTLA-4 antibody ipilimumab achieved a 6-month PFS rate of 59.6%, which was superior to the comparator — a clinically meaningful benchmark of 44%. The results were not the same when a PD-1 inhibitor (nivolumab) were used. That trial arm yielded a poorer 6-month PFS vs the benchmark.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form